Relationship Between the Uric Acid Level and CNS Relapse Risk in Patients with Newly Diagnosed Adult Diffuse Large B Cell Lymphoma

<b>Introduction</b>: Central nervous system (CNS) involvement is reported to represent 5% of extranodal diffuse large B cell lymphoma (DLBCL) at diagnosis. To stratify patients' risk of CNS involvement, the CNS-International Prognostic Index (CNS-IPI) score was developed. Serum uric acid level has not been incorporated into IPI or CNS-IPI score and its correlation with CNS-IPI risk groups and the CNS relapse has not been studied to date. Therefore, we aimed to retrospectively analyze the relationship between uric acid levels and CNS relapse risk in patients with newly diagnosed adult DLBCL. <b>Methods</b>: Ninety-four adult newly diagnosed DLBCL patients were retrospectively assessed via electronic records and patient files. Demographic data, IPI and CNS-IPI scores, hematologic parameters, serum lactate dehydrogenase, beta-2 microglobulin, serum uric acid and creatinine levels at diagnosis were recorded for analysis. Uric acid levels were compared between CNS-IPI low-intermediate and high groups and cumulative incidence of CNS relapses were analyzed between normal and elevated uric acid levels. <b>Results</b>: Uric acid levels were found to be significantly higher in CNS-IPI high-risk patients (<i>p</i> = 0.008). Elevated serum uric acid levels at diagnosis were significantly associated with high CNS-IPI risk in the logistic regression analysis (OR 1.34, 95% CI 1.05-1.78, <i>p</i> = 0.047). Uric acid also higher than 5.39 mg/dL showed a discriminatory ability in ROC analyses (AUC 0.633, 95% CI 0.495-0.771, <i>p</i> = 0.05). In the competing risks regression analysis, accounting for non-CNS-related death and progression as the competing events, CNS-IPI subgroups and uric acid levels were not significantly associated with the cumulative incidence of CNS relapse (SHR 0.81, 95% CI 0.12-5.59; Fine-Gray, <i>p</i> = 0.834), (SHR 0.55, 95% CI 0.09-3.47; Fine-Gray, <i>p</i> = 0.526), respectively. <b>Conclusions</b>: Even though uric acid levels are significantly higher and showed a discriminatory ability to detect the CNS-IPI high subgroup, elevated uric acid levels could not predict the CNS relapses.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Medicine
Published
2026-02-21
DOI
https://doi.org/10.3390/jcm15041642
Primary Topic
CNS Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Relationship Between the Uric Acid Level and CNS Relapse Risk in Patients with Newly Diagnosed Adult Diffuse Large B Cell Lymphoma

Abdullah Karakuş, Vehbi Demircan, Uğur Hatipoğlu, Orhan Ayyıldız
Journal of Clinical Medicine
CNS Lymphoma Diagnosis and Treatment
article

Relationship Between the Uric Acid Level and CNS Relapse Risk in Patients with Newly Diagnosed Adult Diffuse Large B Cell Lymphoma

Abdullah Karakuş, Vehbi Demircan, Uğur Hatipoğlu, Orhan Ayyıldız
article en

Abstract

<b>Introduction</b>: Central nervous system (CNS) involvement is reported to represent 5% of extranodal diffuse large B cell lymphoma (DLBCL) at diagnosis. To stratify patients' risk of CNS involvement, the CNS-International Prognostic Index (CNS-IPI) score was developed. Serum uric acid level has not been incorporated into IPI or CNS-IPI score and its correlation with CNS-IPI risk groups and the CNS relapse has not been studied to date. Therefore, we aimed to retrospectively analyze the relationship between uric acid levels and CNS relapse risk in patients with newly diagnosed adult DLBCL. <b>Methods</b>: Ninety-four adult newly diagnosed DLBCL patients were retrospectively assessed via electronic records and patient files. Demographic data, IPI and CNS-IPI scores, hematologic parameters, serum lactate dehydrogenase, beta-2 microglobulin, serum uric acid and creatinine levels at diagnosis were recorded for analysis. Uric acid levels were compared between CNS-IPI low-intermediate and high groups and cumulative incidence of CNS relapses were analyzed between normal and elevated uric acid levels. <b>Results</b>: Uric acid levels were found to be significantly higher in CNS-IPI high-risk patients (<i>p</i> = 0.008). Elevated serum uric acid levels at diagnosis were significantly associated with high CNS-IPI risk in the logistic regression analysis (OR 1.34, 95% CI 1.05-1.78, <i>p</i> = 0.047). Uric acid also higher than 5.39 mg/dL showed a discriminatory ability in ROC analyses (AUC 0.633, 95% CI 0.495-0.771, <i>p</i> = 0.05). In the competing risks regression analysis, accounting for non-CNS-related death and progression as the competing events, CNS-IPI subgroups and uric acid levels were not significantly associated with the cumulative incidence of CNS relapse (SHR 0.81, 95% CI 0.12-5.59; Fine-Gray, <i>p</i> = 0.834), (SHR 0.55, 95% CI 0.09-3.47; Fine-Gray, <i>p</i> = 0.526), respectively. <b>Conclusions</b>: Even though uric acid levels are significantly higher and showed a discriminatory ability to detect the CNS-IPI high subgroup, elevated uric acid levels could not predict the CNS relapses.

Journal of Clinical MedicineVol. 15(4)
Dicle University (TR), Ministry of Health (TR), University of Health Science (KH), Sağlık Bilimleri Üniversitesi (TR), University of Health Sciences Antigua (AG)
Reduced inequalities
Openalex Percentile: Top 51%
CNS Lymphoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.